Fragment, CJC1295, Ipamorelin 12mg (Blend)

Fragment 176-191

Fragment 176-191 is a small section of human growth hormone sequence (hGH) that has been shown in animal models to enhance fat burning and shift metabolism toward the maintenance of lean body mass[1]-[3]. Research also suggests that fragment 176-191 also lacks many of the side effects caused by hGH such as decreased insulin sensitivity, long-bone growth, and edema. That said, the fragment could contribute to the normal physiologic mechanisms that control GH secretion and could therefore positively affect levels of GH according to recent research studies.

CJC-1295

CJC-1295 could counteract the GH effects of fragment 176-191 as it is a synthetic growth hormone releasing hormone and therefore stimulates the release of G[4]. CJC-1295 acts to increase basal and peak levels of GH and has also been shown to increase free plasma levels of GH. Only free GH is biologically active. CJC-1295 can therefore compensate for a normal physiologic response to fragment 176-191. This would allow for the benefits of fragment 176-191 to be realized without having any impact on normal GH secretion.

To further boost GH secretion above basal levels and to particularly affect peak GH secretion, Ipamorelin could be added to the mix. Ipamorelin is a growth hormone secretagogue receptor agonist that has been shown in animal studies to have potent and specific effects on GH secretion while having very limited side effects[5]. Ipamorelin has also been shown to be highly beneficial to bone mineralization and insulin control in animal models[], [7]. Ipamorelin is a short-acting peptide whereas CJC-1295 is a longer-acting peptide. The former provides rapid onset GH release while the latter acts to raise GH secretion over longer periods and maintain normal physiologic secretion patterns.